U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) Delaware 45-2559340 2080 Century Park East, Suite 906 Los Angeles, CA (Address of principal executive offices) (Zip Code) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission file number 001-38758 RENOVARO BIOSCIENCES INC. (Name of registrant in its charter) | Delaware | | 45-2559340 | | --- | --- | --- | | (State or other jurisdiction of | | (I.R.S. Empl ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-38758 Enochian Biosciences Inc. (Exact name of registrant as specified in its charter) Delaware 45-2559340 (State or other jurisdi ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-38758 Enochian Biosciences Inc. (Exact name of registrant as specified in its charter) Delaware 45-2559340 (State or other juri ...

Commission file number 000-54478 For the fiscal year ended June 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ENOCHIAN BIOSCIENCES INC. (Name of registrant in its charter) | Delaware | 45-2559340 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | i ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-38758 Enochian Biosciences Inc. (Exact name of registrant as specified in its charter) Delaware 45-2259340 (State or other jurisdi ...

Pipeline Expansion - Enochian Biosciences has expanded its pipeline from a single potential cure for HIV to four additional potential cures, including treatments for Hepatitis B Virus (HBV) and various solid tumors [113]. - The company is developing ENOB-HV-01, a novel gene-modified T cell therapy aimed at significantly increasing engraftment and avoiding the need for chemotherapy, with a Pre-IND submission expected soon [127]. - Enochian has an exclusive license for a potential inhaled treatment for SARS-CoV-1 and -2, with promising in vitro and in vivo results presented at a major conference [120][121]. - Enochian's innovative approach to HBV aims to induce the death of liver cells infected with the virus, with a Pre-IND process completed and potential for clinical trials to begin by the end of 2022 or in 2023 [133][137]. - The company is targeting pancreatic cancer, triple-negative breast cancer, glioblastoma, and renal cell carcinoma with a new therapeutic vaccination platform, with initial results expected in the first half of 2022 [138][139]. - Enochian is in the development phase of additional product candidates related to its HIV pipeline, including ENOB-HV-31 and ENOB-HV-32 [130]. Financial Performance - Enochian has never generated sales revenue and expects this to continue until its therapies are approved for marketing in the U.S. and/or Europe [140]. - Operating expenses for the three months ended December 31, 2021, were $6,330,791, an increase of $3,025,575 or approximately 92% compared to the same period in 2020 [148]. - General and administrative expenses for the three months ended December 31, 2021, were $4,154,901, representing an increase of $2,214,914 or approximately 114% compared to the same period in 2020 [150]. - Research and development expenses for the six months ended December 31, 2021, were $5,150,328, an increase of $2,765,484 or approximately 116% compared to the same period in 2020 [153]. - Net loss for the three months ended December 31, 2021, was $6,582,941, an increase of $3,649,645 or approximately 124% compared to the same period in 2020 [156]. - Total assets as of December 31, 2021, were $183,136,138, a decrease from $189,605,225 as of June 30, 2021 [162]. - Total liabilities as of December 31, 2021, were $17,516,675, an increase from $14,942,286 as of June 30, 2021 [163]. - Cash used in operating activities for the six months ended December 31, 2021, was $(9,897,151), compared to $(5,251,828) for the same period in 2020 [165]. - Cash provided by financing activities for the six months ended December 31, 2021, was $2,950,741, compared to cash used of $(40,408) during the same period in 2020 [166]. - The company had $13,707,907 in cash as of December 31, 2021, a decrease of 34% compared to $20,664,410 as of June 30, 2021 [161]. - The company does not anticipate earning any revenues until its therapies or products are approved for marketing and sale [147]. Research and Development Challenges - The COVID-19 pandemic has caused delays in research activities but has not materially affected operations; however, it has increased costs for conducting animal studies [142][144]. - The company has established an HBV Scientific Advisory Board to guide its research and development efforts in HBV treatment and cure [134].

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-38758 Enochian Biosciences Inc. (Exact name of registrant as specified in its charter) Delaware 45-2259340 (State or other jur ...

FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the fiscal year ended June 30, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission file number 000-54478 ENOCHIAN BIOSCIENCES INC. (Name of registrant in its charter) | Delaware | | 45-2559340 | | --- | --- | --- | | (State or other jurisdiction of | | (I.R.S. Empl ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-38758 Enochian Biosciences Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Emp ...